cerebrospinal fluid

Acute endurance exercise modulates growth differentiation factor 11 in cerebrospinal fluid of healthy young adults

Authors: Martin Schön, Karin Marček Malenovská, Michal Nemec, Nikoleta Alchus Laiferová, Igor Straka, Zuzana Košutzká, Peter Matejička, Peter Valkovič, Jozef Ukropec, Barbara Ukropcová

Journal: Frontiers in Endocrinology

Year Published: 2023

Objective Strong evidence supports the benefits of exercise for healthy ageing, including reduced risk of neurodegenerative diseases. Recent studies suggested interorgan crosstalk as a key element of systemic adaptive response, however, the role of specific molecules […]

Switching from a regimen containing abacavir/lamivudine or emtricitabine/tenofovir disoproxil fumarate to emtricitabine/tenofovir alafenamide fumarate does not affect central nervous system HIV-1 infection

Authors: Aylin Yilmaz, Åsa Mellgren, Dietmar Fuchs, Staffan Nilsson, Kaj Blennow, Henrik Zetterberg & Magnus Gisslén

Journal: Infectious Diseases

Year Published: 2019

Background: Despite suppressive antiretroviral therapy (ART), many HIV-infected individuals have low-level persistent immune activation in the central nervous system (CNS). There have been concerns regarding the CNS efficacy of tenofovir alafenamide fumarate (TAF) because of its […]

Associations between Performance on an Abbreviated CogState Battery, Other Measures of Cognitive Function, and Biomarkers in People at Risk for Alzheimer’s Disease

Authors: Annie M Racine, Lindsay R Clark, Sara E Berman, Rebecca L Koscik, Kimberly D Mueller, Derek Norton, Christopher R Nicholas, Kaj Blennow, Henrik Zetterberg, Bruno Jedynak, Murat Bilgel, Cynthia M Carlsson, Bradley T Christian, Sanjay Asthana, Sterling C Johnson

Journal: Journal of Alzheimer's Disease

Year Published: 2016

It is not known whether computerized cognitive assessments, like the CogState battery, are sensitive to preclinical cognitive changes or pathology in people at risk for Alzheimer’s disease(AD). In 469 late middle-aged participants from the Wisconsin Registry […]

A 24-week Study to Evaluate the Effect of Rilapladib on Cognition and Cerebrospinal Fluid Biomarkers of Alzheimer’s Disease

Authors: Gareth Maher-Edwards, Jeni De'Ath, Carly Barnett, Arseniy Lavrov, Andrew Lockhart

Journal: Alzheimer's & Dementia

Year Published: 2015

Background: The lipoprotein-associated phospholipase A2 inhibitor (Lp-PLA2), rilapladib (SB659032), is being evaluated as a potential treatment to slow the progression of Alzheimer’s disease (AD). Methods: One hundred twenty-four subjects with possible mild AD and with neuroimaging […]

Back to Publications